<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430377</url>
  </required_header>
  <id_info>
    <org_study_id>SBPS</org_study_id>
    <nct_id>NCT01430377</nct_id>
  </id_info>
  <brief_title>Side Branch Predilatation Strategy in Coronary Bifurcation Lesion Stenting (SBPS)</brief_title>
  <acronym>SBPS</acronym>
  <official_title>Side Branch Predilatation Strategy in Coronary Bifurcation Lesion Stenting (SBPS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medica Cor Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medica Cor Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of Side Branch (SB) predilatation during coronary bifurcation lesion percutaneous
      coronary intervention (PCI) is still not established. The predilatation could potentially
      damage SB ostium by vessel dissection, making subsequent wiring problematic. However,
      predilatation could eliminate SB ostial stenosis obviating need for further SB treatment
      after main vessel stent implantation. The aim of the study is to assess in random fashion the
      periprocedural myonecrosis, complication rates and time for SB rewiring in groups with and
      without SB predilatation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time for rewiring SB</measure>
    <time_frame>24h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Periprocedural myonecrosis</measure>
    <time_frame>24 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>12 months</time_frame>
    <description>death, MI, TVR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronary Ostium Stenosis</condition>
  <condition>Myonecrosis</condition>
  <arm_group>
    <arm_group_label>SB predilatation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SB predilatation</intervention_name>
    <description>Initial SB [predilatation.</description>
    <arm_group_label>SB predilatation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No SB predilatation</intervention_name>
    <description>Without SB predilatation</description>
    <arm_group_label>SB predilatation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Inclusion Criteria

               -  Subject at least 18 years of age.

               -  Subject able to verbally confirm understandings of risks, benefits of receiving
                  PCI for true bifurcation lesions, and he/she or his/her legally authorized
                  representative provides written informed consent prior to any study related
                  procedure.

               -  Target main branch lesion(s) located in a native coronary artery with diameter of
                  ≥ 2.5 mm and ≤ 4.5 mm. Target side branch lesion(s) located in a native coronary
                  artery with diameter of ≥ 2.0 mm.

               -  Target lesion(s) amenable for PCI with balloon angioplasty of the side branch.

          2. Exclusion Criteria

               -  ST-segment elevation myocardial infarction (STEMI)

               -  Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that
                  may result in protocol non-compliance (per site investigator's medical judgment).

               -  Subjects who refuse to give informed consent.

               -  Subjects with left ventricle ejection fraction &lt;30%

               -  Subjects with moderate or severe degree valvular heart disease or primary
                  cardiomyopathy

               -  Contraindications for 12 months double antiplatelet therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dobrin I Vassilev, MD, PhD</last_name>
    <phone>00359886846550</phone>
    <email>dobrinv@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medica Cor Heart Hospital</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dobrin I Vassilev, MD, PhD</last_name>
      <phone>00359886846550</phone>
      <email>dobrinv@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hristo Popov, MD</last_name>
      <phone>00359887686003</phone>
      <email>hrpopov@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2011</study_first_submitted>
  <study_first_submitted_qc>September 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2011</study_first_posted>
  <last_update_submitted>September 7, 2011</last_update_submitted>
  <last_update_submitted_qc>September 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medica Cor Heart Hospital</investigator_affiliation>
    <investigator_full_name>Dobrin Vassilev MD, PhD</investigator_full_name>
    <investigator_title>Dobrin Vassilev MD, PhD</investigator_title>
  </responsible_party>
  <keyword>periprocedural myonecrosis</keyword>
  <keyword>procedure time</keyword>
  <keyword>fluoroscopy time</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

